MD-2 as the Target of Nonlipid Chalcone in the Inhibition of Endotoxin LPS-Induced TLR4 Activity

Dual Signaling of MyD88 and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation

(2014) H. Shen et al.   JOURNAL OF IMMUNOLOGY

α-Viniferin Suppresses the Signal Transducer and Activation of Transcription-1 (STAT-1)–Inducible Inflammatory Genes in Interferon-γ–Stimulated Macrophages

(2010) Eun Yong Chung et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Xanthohumol and Related Prenylated Flavonoids Inhibit Inflammatory Cytokine Production in LPS-Activated THP-1 Monocytes: Structure-Activity Relationships andIn SilicoBinding to Myeloid Differentiation Protein-2 (MD-2)

(2010) Michael Peluso et al.   PLANTA MEDICA

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

(2009) Mark Tidswell et al.   CRITICAL CARE MEDICINE

Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation

(2009) Mateja Manček-Keber et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

(2009) Beom Seok Park et al.   NATURE

Modification of the cysteine residues in I B  kinase and NF- B (p65) by xanthohumol leads to suppression of NF- B-regulated gene products and potentiation of apoptosis in leukemia cells

(2008) K. B. Harikumar et al.   BLOOD

Benzoxathiole Derivative Blocks Lipopolysaccharide-Induced Nuclear Factor- B Activation and Nuclear Factor- B-Regulated Gene Transcription through Inactivating Inhibitory  B Kinase  

(2008) B. H. Kim et al.   MOLECULAR PHARMACOLOGY

Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases

(2008) Carlos G. Leon et al.   PHARMACEUTICAL RESEARCH